Serum adiponectin levels are associated with worse cognitive function in postmenopausal women
- PMID: 29267309
- PMCID: PMC5739380
- DOI: 10.1371/journal.pone.0186205
Serum adiponectin levels are associated with worse cognitive function in postmenopausal women
Abstract
Introduction: Adiponectin may be a biomarker of cognitive impairment stage, and its clinical progression. In this study we aimed to evaluate the relationship between serum adiponectin levels and cognitive performances in menopausal women, and whether serum adiponectin levels may be differently associated with cognitive performances as compared to overweight/obese subjects.
Methods: We enrolled 188 post-menopausal women, divided into two groups: obese/overweight group (n = 96) and normal weight group (n = 92). After a clinical examination, and laboratory measurements, we assessed cognitive functions by Montreal Cognitive Assessment test (MoCA).
Results: A significant and greater decrease in executive/visuo-spatial and in attention functions occurred in obese/overweight group as compared to normal weight group (p< 0.001). A significant positive relationship between serum adiponectin levels, and MoCA Global cognitive function was found. MoCA executive, and MoCA attention functions significantly and positively correlated with serum adiponectin levels. BMI, WHR, and serum adiponectin levels were independently associated with MoCA Global cognitive function, but only serum adiponectin levels were independently associated with MoCA attention.
Conclusion: A significant positive association may exist between serum adiponectin levels, and better cognitive function in postmenopausal status. The major determinant of attentional capacity was just serum adiponectin levels, and dosage of serum adiponectin levels may be early serum marker of cognitive decline. Therefore, serum adiponectin level has to be used, as early biomarker, to detect cognitive decline, and to support an early prevention.
Conflict of interest statement
References
-
- Rettberg JR., Dang H, Hodis HN., Henderson VW, St. John J A, Mack WJ, Diaz Brinton R. Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer’s risk metabolic phenotype. Neurobiology of Aging 2016: 40, 155–163 doi: 10.1016/j.neurobiolaging.2016.01.011 - DOI - PMC - PubMed
-
- Siervo M, Harrison SL, Jagger C, Robinson L, Stephan BC. Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(1):151–61 doi: 10.3233/JAD-132279 - DOI - PubMed
-
- Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 2012; 42, 484–491 doi: 10.1111/j.1445-5994.2012.02758.x - DOI - PubMed
-
- Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, Coresh J, Knopman D, Power MC, Rawlings A, Sharrett AR, Wruck LM, Mosley TH. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014; 71, 1218–1227 doi: 10.1001/jamaneurol.2014.1646 - DOI - PMC - PubMed
-
- Cohen Ronald A. Obesity-Associated Cognitive Decline: Excess Weight Affects More than the Waistline. Neuroepidemiology 2010;34:230–231 doi: 10.1159/000297745 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources